Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Presented by

Eric Henry, PharmD, Clinical Content Specialist with Clinical Effectiveness at Wolters Kluwer, Heath

About this talk

Join Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: •The potential impact of biosimilars at this tipping point in the pharmaceutical industry •FDA-required suffixes and standards for biosimilars naming •Prescription workflow best practices for small and large molecule biosimilars •Issues raised by retrospective naming and products without suffixes The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products. This is an open event. Share on Twitter, Facebook, and LinkedIn now! This webinar is organized by Wolters Kluwer, the maker of Medi-Span®, Lexicomp®, Emmi® patient programs, and UpToDate®.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (11)
Subscribers (296)
Wolters Kluwer Clinical Effectiveness - sharing thought leadership across healthcare segments.